• 2021.0416

    In February 2021, Chinese guidelines for diagnosis and treatment of diabetic kidney disease (Registration number: IPGRP-2021CN035) were published online by the Chinese Society of Nephrology in the Chinese Journal of Nephrology. The guideline is based on domestic and international expert consensus and integrates the clinical experience of Chinese nephrologists. This guideline contains the diagnosis of diabetic kidney disease (DKD), renal pathology biopsy, treatment and management, management of complications, and rational application of commonly used drugs. The expert group has referred to the international guideline format in the preparation process based on the principles of rigor, conciseness, and authority. The guidelines reflect new trends and perspectives in the treatment of DKD and are of great value in further strengthening the understanding of DKD, standardizing the treatment system, formulating reasonable treatment principles, guiding the precise use of drugs, delaying the progression of kidney disease. It will improve the life quality of patients and could be used by physicians for reference in clinical work.

  • 2021.0416

    The Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement, published in 2009, was designed to help to improve the reporting quality of the systematic reviews. The first edition of the PRISMA statement has been published over 10 years. Over the past decade, advances in systematic review methodology and terminology have necessitated an update to the guideline.

  • 2021.0331

    In January 2021,Runsheng Xie published an article in Pharmacological Research entitled The RIGHT Extension Statement for Traditional Chinese Medicine: Development, Recommendations, and Explanation. Nowadays, the number of traditional Chinese medicine (TCM) guidelines is constantly increasing, but its reporting quality remains unsatisfactory. The group hopes that the RIGHT-TCM may assist TCM guideline developers in reporting guidelines, support journal editors and peer reviewers when considering TCM guideline reports, and help health care practitioners understand and implement a TCM guideline.

  • 2021.0319

    Registration is a way for researchers to provide key features from their protocol and results which are recorded and published progressively through an online and open platform. In 2007, the International Clinical Trial Registry Platform (ICTRP) based at the World Health Organization (WHO) was established, enabling the full implementation of the clinical trial registry. In 2011, an International Prospective Register of Systematic Reviews (PROSPERO) was developed, so that registration of systematic reviews/Meta-analysis was gradually recognized and applied. Compared with the clinical trials and systematic reviews, clinical practice guidelines (CPGs) are important guidance documents for medical practice. However, prospective registration for CPGs has become relatively late with lacking attention for its importance and significance. The concept, methods and approaches of registration for CPGs have also not been fully discussed by researchers, guideline developers and journal editors for a long time.

  • 2021.0315

    In March 7, 2021, Tanja A Stamm, et al published an article entitled “The methodological quality is insufficient in clinical practice guidelines in the context of COVID-19: systematic review” in the Journal of Clinical Epidemiology. This study systematic searched clinical practice guidelines or recommendations related to Corona Virus Disease 2019 (COVID-19), and assessed their methodological quality by using the Appraisal of Guidelines for Research and Evaluation II (AGREE II) tool.

Register MORE
  • 2021.0419
    Off-label drug use in ophthalmology is widespread in different medical institutions in China. However, there are only scattered studies evaluating its effectiveness and safety, and no unified conclusion has been reached yet. We plan to systematically evaluate the rationality of current off-label drug use in domestic medical institutions in order to develop evidence-based evaluation guidelines for off-label drug use in ophthalmology in China, so as to provide evidence support for rational drug use in ophthalmology and promote safe and correct drug use.
  • 2021.0417
    经鼻高流量湿化氧疗(humidified high-flow nasal cannula oxygen therapy,HFNC)是一种通过无需密封的导管经鼻输入加温湿化的高流量混合气体的呼吸治疗方式。HFNC 设备由空氧混合器装置、主动加温装置、加热导丝单回路管路和鼻导管组成(附图 1),可提供准确的氧浓度(21%-100%),充分加温加湿( 37℃、绝对湿度 44 mgH2O/L、相对湿度 100%),流量最高达 60-75 L/min 的气体。越来越多的证据表明[1, 2], HFNC 对于呼吸衰竭,呼吸困难有显著的临床治疗效果,并且患者的耐受性好,操作简单易学。HFNC已经与传统鼻导管氧疗(Conventional Oxygen Therapy, COT),无创正压通气(Noninvasive Positive Pressure Ventilation, NIPPV), 有创机械通气(Invasive Mechanical Ventilation, IMV)共同成为急诊急救中常用的呼吸治疗方式。 目前,国内和国际有关HFNC指南或专家共识主要有中华医学会呼吸病学分会发布的成人经鼻高流量湿化氧疗临床规范应用专家共识[3],欧洲重症监护医学学会(European Society of Intensive Care Medicine, ESICM)发布的经鼻高流量湿化氧疗在成人呼吸支持策略中的临床实践指南[4]。而国内针对HFNC在急诊急救中应用的共识和指南尚不完善。为促进国内急诊同道规范有效安全地使用HFNC,拟制定本推荐意见,作为HFNC在成人急诊临床应用的主要参考。 本共识着重解答以下几个问题:① HFNC治疗急性呼吸衰竭的急诊流程。明确 COT、HFNC、NIV在急诊救治呼吸衰竭患者时的应用关系。②在成人急诊使用HFNC时 的适应证和禁忌证。逐步扩展HFNC在急诊应用的适应证,强调禁忌证。③使用HFNC 时监测和预测治疗效果。提高HFNC治疗各类呼吸衰竭患者的安全性。
Registration process and operational mode of a CPG registry